from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary: ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 30 Jun 2010 to 31 Dec 2025.
ELITE PHARMACEUTICALS INC /NV/ Nonoperating Income (Expense) for the quarter ending 31 Dec 2025 was $11,820,773.
ELITE PHARMACEUTICALS INC /NV/ Nonoperating Income (Expense) for the twelve months ending 31 Dec 2025 was $5,151,693.
ELITE PHARMACEUTICALS INC /NV/ annual Nonoperating Income (Expense) for 2024 was $19,652,608, a 90% decline from 2023.
ELITE PHARMACEUTICALS INC /NV/ annual Nonoperating Income (Expense) for 2023 was $10,325,677, a 3432% decline from 2022.
ELITE PHARMACEUTICALS INC /NV/ annual Nonoperating Income (Expense) for 2022 was $309,872, a 75% decline from 2021.
Source SEC data: View on sec.gov

Nonoperating Income (Expense), Trailing 12 Months (USD)

Nonoperating Income (Expense), Quarterly (USD)

Nonoperating Income (Expense), YoY Quarterly Change (%)

Nonoperating Income (Expense), Annual (USD)

Nonoperating Income (Expense), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Nonoperating Income (Expense) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$5,151,693	$11,820,773	+$23,571,348		01 Oct 2025	31 Dec 2025	10-Q	17 Feb 2026	2026	Q3
Q3 2025	$18,419,655	$7,476,601	+$20,480,570		01 Jul 2025	30 Sep 2025	10-Q	14 Nov 2025	2026	Q2
Q2 2025	$38,900,225	$22,263,921	-$19,247,617	-638%	01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2026	Q1
Q1 2025	$19,652,608	$8,118,240	+$9,853,451		01 Jan 2025	31 Mar 2025	10-K	30 Jun 2025	2025	FY
Q4 2024	$29,506,059	$11,750,575	-$8,123,660	-224%	01 Oct 2024	31 Dec 2024	10-Q	17 Feb 2026	2026	Q3
Q3 2024	$21,382,399	$13,003,969	-$8,345,681	-179%	01 Jul 2024	30 Sep 2024	10-Q	14 Nov 2025	2026	Q2
Q2 2024	$13,036,718	$3,016,304	-$2,711,041	-888%	01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2026	Q1
Q1 2024	$10,325,677	$1,735,211	-$1,266,047	-270%	01 Jan 2024	31 Mar 2024	10-K	30 Jun 2025	2025	FY
Q4 2023	$9,059,630	$3,626,915	-$4,677,143	-445%	01 Oct 2023	31 Dec 2023	10-Q	13 Feb 2025	2025	Q3
Q3 2023	$4,382,487	$4,658,288	-$5,103,897	-1145%	01 Jul 2023	30 Sep 2023	10-Q	14 Nov 2024	2025	Q2
Q2 2023	$721,410	$305,263	+$411,538	+57%	01 Apr 2023	30 Jun 2023	10-Q	14 Aug 2024	2025	Q1
Q1 2023	$309,872	$469,164	-$305,789	-187%	01 Jan 2023	31 Mar 2023	10-K	01 Jul 2024	2024	FY
Q4 2022	$615,661	$1,050,228	+$598,115	+132%	01 Oct 2022	31 Dec 2022	10-Q	14 Feb 2024	2024	Q3
Q3 2022	$17,546	$445,609	+$69,238	+18%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2023	2024	Q2
Q2 2022	$51,692	$716,801	-$1,285,411	-226%	01 Apr 2022	30 Jun 2022	10-Q	14 Aug 2023	2024	Q1
Q1 2022	$1,233,719	$163,375			01 Jan 2022	31 Mar 2022	10-K	29 Jun 2023	2023	FY
Q4 2021		$452,113	-$558,851	-55%	01 Oct 2021	31 Dec 2021	10-Q	14 Feb 2023	2023	Q3
Q3 2021		$376,371			01 Jul 2021	30 Sep 2021	10-Q	14 Nov 2022	2023	Q2
Q2 2021		$568,610			01 Apr 2021	30 Jun 2021	10-Q	15 Aug 2022	2023	Q1
Q4 2020		$1,010,964			01 Oct 2020	31 Dec 2020	10-Q	14 Feb 2022	2022	Q3
Q1 2018	$4,332,000	$203,000	-$4,203,000	-105%	01 Jan 2018	31 Mar 2018	10-K	14 Jun 2018	2018	FY
Q4 2017	$8,535,000	$517,000	-$1,002,000	-66%	01 Oct 2017	31 Dec 2017	10-K	14 Jun 2018	2018	FY
Q3 2017	$9,537,000	$3,945,000	-$1,498,000	-28%	01 Jul 2017	30 Sep 2017	10-K	14 Jun 2018	2018	FY
Q2 2017	$11,035,000	$73,000	-$2,261,000	-97%	01 Apr 2017	30 Jun 2017	10-K	14 Jun 2018	2018	FY
Q1 2017	$13,296,000	$4,000,000	-$3,408,000	-46%	01 Jan 2017	31 Mar 2017	10-K	14 Jun 2018	2018	FY
Q4 2016	$16,704,000	$1,519,000	+$11,039,000		01 Oct 2016	31 Dec 2016	10-K	14 Jun 2018	2018	FY
Q3 2016	$5,665,000	$5,443,000	+$3,357,000	+161%	01 Jul 2016	30 Sep 2016	10-K	14 Jun 2018	2018	FY
Q2 2016	$2,308,000	$2,334,000	-$4,805,000	-67%	01 Apr 2016	30 Jun 2016	10-K	14 Jun 2018	2018	FY
Q1 2016	$7,113,000	$7,408,000	+$8,306,000		01 Jan 2016	31 Mar 2016	10-K	14 Jun 2018	2018	FY
Q4 2015	$1,193,000	$9,520,000	-$19,494,000	-195%	01 Oct 2015	31 Dec 2015	10-K	14 Jun 2018	2018	FY
Q3 2015	$18,301,000	$2,086,000	-$8,224,000	-80%	01 Jul 2015	30 Sep 2015	10-K	14 Jun 2018	2018	FY
Q2 2015	$26,525,000	$7,139,000	+$4,801,000	+205%	01 Apr 2015	30 Jun 2015	10-K	14 Jun 2018	2018	FY
Q1 2015	$21,724,000	$898,000	+$30,754,000	+97%	01 Jan 2015	31 Mar 2015	10-K	14 Jun 2017	2017	FY
Q4 2014	$9,030,000	$9,974,000	+$9,799,000	+5599%	01 Oct 2014	31 Dec 2014	10-K	14 Jun 2017	2017	FY
Q3 2014	$18,829,000	$10,310,000	+$17,197,000		01 Jul 2014	30 Sep 2014	10-K	14 Jun 2017	2017	FY
Q2 2014	$36,026,000	$2,338,000	+$243,000	+12%	01 Apr 2014	30 Jun 2014	10-K	14 Jun 2017	2017	FY
Q1 2014	$36,269,000	$31,652,000	-$33,179,099	-2173%	01 Jan 2014	31 Mar 2014	10-K	15 Jun 2016	2016	FY
Q4 2013	$3,089,901	$175,000	-$9,462,376	-98%	01 Oct 2013	31 Dec 2013	10-K	15 Jun 2016	2016	FY
Q3 2013	$6,372,475	$6,887,000	-$8,453,200	-540%	01 Jul 2013	30 Sep 2013	10-K	15 Jun 2016	2016	FY
Q2 2013	$14,825,675	$2,095,000	+$12,128,332		01 Apr 2013	30 Jun 2013	10-K	15 Jun 2016	2016	FY
Q1 2013	$2,697,343	$1,527,099	+$8,411,661		01 Jan 2013	31 Mar 2013	10-K	30 Jun 2014	2014	FY
Q4 2012	$5,714,318	$9,637,376	+$445,431	+4.8%	01 Oct 2012	31 Dec 2012	10-Q	14 Feb 2014	2013	Q3
Q3 2012	$6,159,749	$1,566,200	-$12,944,723	-89%	01 Jul 2012	30 Sep 2012	10-Q	14 Nov 2013	2013	Q2
Q2 2012	$6,784,974	$10,033,332	+$20,361,062	+67%	01 Apr 2012	30 Jun 2012	10-Q	14 Aug 2013	2013	Q1
Q1 2012	$13,576,088	$6,884,562	+$9,299,039	+57%	01 Jan 2012	31 Mar 2012	10-K	21 Jun 2013	2012	FY
Q4 2011	$22,875,127	$9,191,945	+$3,335,602	+57%	01 Oct 2011	31 Dec 2011	10-Q	14 Feb 2013	2012	Q3
Q3 2011	$26,210,729	$14,510,923	+$12,508,852	+625%	01 Jul 2011	30 Sep 2011	10-Q	14 Nov 2012	2012	Q2
Q2 2011	$38,719,581	$30,394,394	-$25,721,769	-550%	01 Apr 2011	30 Jun 2011	10-Q	14 Aug 2012	2012	Q1
Q1 2011	$12,997,812	$16,183,601			01 Jan 2011	31 Mar 2011	10-K	29 Jun 2012	2011	FY
Q4 2010		$5,856,343			01 Oct 2010	31 Dec 2010	10-Q	14 Feb 2012	2011	Q3
Q3 2010		$2,002,071			01 Jul 2010	30 Sep 2010	10-Q	14 Nov 2011	2011	Q2
Q2 2010		$4,672,625			01 Apr 2010	30 Jun 2010	10-Q/A	19 Aug 2011	2011	Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Nonoperating Income (Expense) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$19,652,608	-$9,326,931	-90%	01 Apr 2024	31 Mar 2025	10-K	30 Jun 2025	2025	FY
2023	$10,325,677	-$10,635,549	-3432%	01 Apr 2023	31 Mar 2024	10-K	30 Jun 2025	2025	FY
2022	$309,872	-$923,847	-75%	01 Apr 2022	31 Mar 2023	10-K	01 Jul 2024	2024	FY
2021	$1,233,719	-$806,272	-40%	01 Apr 2021	31 Mar 2022	10-K	29 Jun 2023	2023	FY
2020	$2,039,991			01 Apr 2020	31 Mar 2021	10-K	29 Jun 2022	2022	FY
2015	$7,113,336	-$14,610,992	-67%	01 Apr 2015	31 Mar 2016	10-K	15 Jun 2016	2016	FY
2014	$21,724,328	+$57,994,212		01 Apr 2014	31 Mar 2015	10-K	15 Jun 2016	2016	FY
2013	$36,269,884	-$38,967,227	-1445%	01 Apr 2013	31 Mar 2014	10-K	15 Jun 2016	2016	FY
2012	$2,697,343	+$16,273,431		01 Apr 2012	31 Mar 2013	10-K	30 Jun 2014	2014	FY
2011	$13,576,088	-$578,276	-4.4%	01 Apr 2011	31 Mar 2012	10-K	21 Jun 2013	2012	FY
2010	$12,997,812			01 Apr 2010	31 Mar 2011	10-K	29 Jun 2012	2011	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.